+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plaque Psoriasis - Global Drug Forecast and Market Analysis to 2030

  • ID: 5517608
  • Report
  • November 2021
  • Region: Global
  • 108 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Psoriasis is an incurable, chronic and systemic inflammatory skin disorder with a prevalence of 2–3% worldwide. The exact causes of psoriasis is unknown, although it is believed that environmental factors, skin barrier disruptions, and immune dysfunctions are key components that induce the development of psoriasis. The most common form of psoriasis is plaque psoriasis (psoriasis vulgaris), which is the focus of this report.

The plaque psoriasis (PsO) market is currently at an important commercial juncture. The field has been dominated over the last twenty years by injectable biologics, with more innovative and efficacious therapies launching in the last five years. However, the market is expected to evolve significantly over the next 10 years as several key patents expire and drug manufacturers move away from injectable biologics and towards novel mechanisms of action.

Key Highlights


  • The greatest drivers of growth in the global PsO market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the PsO market include the patent expiration of several key biologics and small molecules.
  • Among the late-stage innovator pipeline products, three are injectable biologics, three are oral small molecules, and two are topical small molecules.
  • The most important unmet needs in the PsO market are increased access to therapies as well as therapies that can target the multiple disease domains.

KEY QUESTIONS ANSWERED


  • Which unmet needs are limiting the treatment of PsO in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for PsO? How should these strategies differ across different geographical markets?
  • What effect will the launch of biosimilars and generics have on the sales of branded agents? What can drug manufacturers do in order to ensure the success of their biosimilars?
  • What are the main R&D trends in the PsO market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope


  • Overview of PsO including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline PsO market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsO therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy


The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PsO therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsO market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsO therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Plaque Psoriasis: Executive Summary
1.1 PsO Market to Experience Conservative Growth from 2020–2030
1.2 New Players to Enter a Saturated Field
1.3 Opportunities Remain for Undertreated Patient Populations
1.4 Innovator Small Molecules Dominate the Late-Stage Pipeline
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for PsO (2020–2030)
4.6 Discussion
5 Disease Management
5.1 Diagnosis
5.2 Treatment
6 Competitive Assessment
6.1 Overview
6.2 Biosimilars
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Cost-Effective Therapies
7.3 Efficacious Therapies for Treatment Refractory Patients
7.4 Lack of Innovative Topical Therapies
7.5 Treatment Options for Mild PsO Patients
8 R&D Strategies
8.1 Overview
8.2 Clinical Trials Design
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs of Note
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.2 US
12.3 5EU
12.4 Japan
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary Research – KOLs and Payors Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
  • Contact The Publisher

List of Tables
Table 1: Plaque Psoriasis: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbidities for PsO
Table 3: Classification of PsO by BSA
Table 4: Treatment Guidelines for Plaque Psoriasis
Table 5: Top Completed Deals in PsO Market by Value, 2016–2021
Table 6: PsO Market – Global Drivers and Barriers, 2020–2030
Table 7: Key Events Impacting Sales for PsO in the US, 2020–2030
Table 8: PsO Market – Drivers and Barriers in the US, 2020–2030
Table 9: Key Events Impacting Sales for PsO in the 5EU, 2020–2030
Table 10: PsO Market – Drivers and Barriers in the 5EU, 2020–2030
Table 11: Key Events Impacting Sales for PsO in Japan, 2020–2030
Table 12: PsO Market – Drivers and Barriers in Japan, 2020–2030
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for PsO in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in PsO During the Forecast Period
Figure 3: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira
Figure 4: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)
Figure 5: Biologic Targets in the Treatment of PsO
Figure 6: 7MM, Lifetime Diagnosed Prevalence of Pediatric PsO (%), Boys and Girls, Ages =17 Years, 2020
Figure 7: 7MM, Lifetime Diagnosed Prevalence of Adult PsO (%), Men and Women, Ages =18 Years, 2020
Figure 8: Sources Used for Lifetime Diagnosed Prevalent Cases of Pediatric PsO
Figure 9: Sources Used and Not Used for Lifetime Diagnosed Prevalent Cases of PsO in Adults
Figure 10: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO by Severity Among Adults
Figure 11: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO with PsA Among Adults
Figure 12: 7MM, Lifetime Diagnosed Prevalent Cases of PsO, Men and Women, All Ages, 2020 (N)
Figure 13: Age-Specific Lifetime Diagnosed Prevalent Cases of PsO, 7MM, Men and Women, 2020 (N)
Figure 14: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO, All Ages, 2020 (N)
Figure 15: 7MM, Lifetime Diagnosed Prevalent Cases of PsO by Severity, Men and Women, =18 Years, 2020
Figure 16: 7MM, Lifetime Diagnosed Prevalent Cases of PsO with Psoriatic Arthritis, Men and Women, =18 Years, 2020 (N)
Figure 17: Overall Treatment Algorithm for PsO and PsO/PsA
Figure 18: Unmet Needs and Opportunities in PsO
Figure 19: Overview of the Development Pipeline in PsO
Figure 20: Key Late-Stage Trials for the Promising Pipeline Agents that The Publisher Expects to Be Licensed for PsO in the 7MM During the Forecast Period
Figure 21: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira (adalimumab)
Figure 22: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)
Figure 23: Analysis of the Company Portfolio Gap in PsO During the Forecast Period
Figure 24: Global (7MM) Sales Forecast by Country for PsO in 2020 and 2030
Figure 25: Sales Forecast by Class for PsO in the US in 2020 and 2030
Figure 26: Sales Forecast by Class for PsO in the 5EU in 2020 and 2030
Figure 27: Sales Forecast by Class for PsO in Japan in 2020 and 2030

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie
  • Pfizer
  • Johnson & Johnson (J&J)
  • Bristol-Myers Squibb
  • UCB Pharma
  • Amgen
  • Novartis
  • Eli Lilly
  • Sun Pharma
  • Dermavant
  • Arcutis Biotherapeutics
  • Merck
  • Dr. Reddy’s Laboratories
  • Affibody
  • Can-Fite BioPharma